Valneva meets with investors as decision on its Lyme vaccine looms

Regulatory decisions expected within twelve months

Valneva plans to participate in interactive discussions at several of these conferences, alongside meetings with institutional investors. The group specified that regulatory decisions are expected "over the next twelve months" for its Lyme disease vaccine candidate, developed in partnership with Pfizer. The company will also provide updates on advances in its research and development portfolio. It will finally address long-term value creation prospects "in the event of regulatory approval and successful commercialization of the Lyme disease vaccine candidate by Pfizer".

Schedule spanning October 15 to November 16

The first event is the Portzamparc BNP Paribas Biotech & Health seminar on October 15 at 11:30 a.m. (Paris time), in the form of a virtual presentation to a group of investors. This will be followed by the Guggenheim 3rd Annual Healthcare Innovation Conference in Boston on November 9 at 9:30 a.m. (Eastern Time), then the Stifel 2026 Healthcare Conference in New York on November 10 at 8:40 a.m. (Eastern Time). The cycle will conclude in London with the Jefferies London Healthcare Conference on November 16 at 2:00 p.m. (Greenwich Mean Time). These three final events combine interactive discussion and meetings with investors. A recording of the presentation will be made available in the "Investors" section of Valneva's website. Investors wishing to meet with management are invited to contact a representative of one of the organizing banks.